Introduction
============

17&-estradiol (E~2~) is the main estrogenic hormone that through the estrogen receptors (ER) acts on the mammary gland regulating a wide variety of biological processes including differentiation, cell proliferation, and development at puberty and during sexual maturity. E~2~ may be procancerogenic by inducing (i) ER-mediated cell proliferation, (ii) gene mutation through a cytochrome P450-mediated metabolic activation, and (iii) aneuploidy ([@bib85]), through overexpression of Aurora-A (Aur-A), a centrosome kinase, and centrosome amplification ([@bib57]). In addition, in both ER+ and ER& breast cancer cells, E~2~ may induce chromatin structural changes through the estrogen-related receptors (ERR) ([@bib38]). Although high levels of E~2~ are implicated in breast cancer in postmenopausal women ([@bib7]), constant low E~2~ concentrations, in the range of picograms, are sufficient to increase breast cancer risk in premenopausal women ([@bib17]).

Tamoxifen (TAM) is a non-steroidal anti-estrogen with partial agonistic activity, extensively used in the treatment of ER&-positive breast cancer. Response to TAM is frequently of limited duration due to the development of resistance ([@bib72], [@bib40]). Although ER& positivity is a well-established predictor of response to TAM and ER&-negative patients are considered nonresponders, it is known that 5--10% of  ER&-negative tumors do benefit from adjuvant TAM treatment ([@bib66], [@bib27], [@bib28], [@bib29], [@bib34]).

Paradoxically, it has been reported that TAM possesses a high mutagenic potential causing chromosome ruptures in animal models ([@bib67]). However, data on type and frequency of chromosome abnormalities induced by TAM are scant ([@bib67]). In particular, cytogenetic studies about the effects of low doses of TAM, as it is suggested for treatment of pre-invasive low-grade breast lesions (e.g., low-grade ductal carcinomas *in situ* or lobular intraepithelial neoplasia), are limited ([@bib48]). The nature of E~2~- or TAM-induced chromosomal damage has been explored using relatively high concentrations of these agents, and only some numerical aberrations and chromosomal breaks have been analyzed ([@bib98], [@bib67], [@bib76], [@bib48]).

The aim of this study was to determine the effects of low doses of E~2~ and TAM on chromosomal rearrangements by comparing the results of conventional karyotyping and multicolor fluorescence *in situ* hybridization (M-FISH) painting with cell proliferation activity of human breast cancer cells with differential expression of ER and HER2.

Materials and methods
=====================

Cell lines
----------

The human breast cancer cell lines MCF7 and T47D (ER+/progesterone receptor (PR)+/HER2&), BT474 (ER+/PR+/HER2+), and SKBR3 (ER&/PR&/HER2+) were obtained from the American Type Culture Collection (ATCC) in March 2010. Cell lines were expanded and stocked at &80°C and cells obtained from these stocks were thawed and used for the experiments. At the end of experiments, short tandem repeat (STR) profiles were performed to confirm the authentication of the cell lines used. All experiments were carried out in each cell line at passages (P) below 30.

MCF7 (P19), T47D (P20), and SKBR3 (P16) were cultured in RPMI-1640 medium (Sigma), whereas BT474 (P18) was cultured in DMEM medium (Sigma). All culture media were supplemented with 10% fetal bovine serum (FBS) (Sigma), antibiotic--antimycotic solution (1X) (Sigma), and [l]{.smallcaps}-glutamine (2 mM) (Invitrogen GmbH). Cells growing in 75 cm^2^ flasks were maintained at 37°C and 5% CO~2~. The absence of contamination with mycoplasma was demonstrated by PCR assay.

E~2~ and TAM treatment
----------------------

In order to remove endogenous serum steroids and exclude the weak estrogen agonistic activity of phenol red ([@bib9]), 48 h before the addition of E~2~ (E2758; Sigma) and TAM (T5648; Sigma) cells were washed with 5 mL phosphate-buffered saline (PBS) and then switched to phenol red-free RPMI-1640 (Sigma) containing 10% charcoal-stripped FBS (Sigma). E~2~ and TAM were dissolved in absolute ethanol and diluted in the media at 10^&8 ^mol L^&1^ and 10^&6 ^mol L^&1^, respectively, and then added to the culture medium at 24, 48, and 96 h. These concentrations have been demonstrated to be the lowest to induce an effect on the architecture of the cytoskeleton in breast cancer cells *in vitro* ([@bib86]).

Cells without treatment at 24 h (T24 h) and at 96 h (T96 h) were used as controls.

Proliferation assay
-------------------

Cells were seeded at a density of 2.5--5 × 10^3^ cells per 100 &L of phenol red-free medium in a 96 multi-well plate and after 24 h were treated with E~2~ and TAM for 24, 48, and 96 h. At the end of each treatment, cell proliferation was assessed using the cell proliferation ELISA kit, BrdU (Roche Diagnostics Deutschland GmbH). Measurement of absorbance was performed by using a MultiSkan Bichromatic reader (Labsystems, Midland, Canada) against a background control as blank. Each treatment was performed in 24 replicates and expressed as means ± standard deviation ([s.d.]{.smallcaps}).

Metaphase spreads and G-banding
-------------------------------

To determine whether E~2~ and TAM treatment resulted in the induction of chromosomal abnormalities, we performed conventional and molecular cytogenetic analysis in parallel with the evaluation of cell proliferation. Metaphases were obtained by using standardized harvesting protocols in order to perform conventional and molecular cytogenetic analysis (multi-FISH and FISH). Briefly, colcemid solution (0.03 &g/mL) (Sigma) was added to cultures 2.5 h before cell harvesting; cells were then treated with hypotonic solution, fixed three times with Carnoy's fixative (3:1 methanol to acetic acid), and spread on glass. For analysis of chromosomal alterations, the slides were banded with G-banding. Glass slides were baked at 70°C for 24 h, incubated in HCl, and placed in 2xSSC buffer before treatment with Wright's stain. Metaphase image acquisition and subsequent karyotyping were performed using a Nikon microscope with the cytogenetic software CytoVision System (Applied Imaging, Santa Clara, CA, USA). According to the International System of Cytogenetic Nomenclature ([@bib91]) "The general rule in tumor cytogenetics is that only the clonal chromosomal abnormalities should be reported", whereas a minimal number of metaphases to be analyzed is not indicated. In this respect, we indicated only those alterations present in at least two metaphases, which is indicative of clonal chromosomal alterations ([@bib91]). Based on these premises, we systematically analyzed 100 metaphases in order to establish the frequency of ploidy after treatments, by counting the number of chromosomes. As a second step, out of these metaphases, only those with good morphology and proper separation of chromosomes were analyzed by M-FISH and G-banding (between 11 and 26). Chromosome aberrations were described according to the International System of Human Cytogenetic Nomenclature (ISCN 2013) ([@bib91]).

Multi-FISH (M-FISH)
-------------------

M-FISH was performed with the aim of identifying complex chromosomal rearrangements. The probe cocktail containing 24 differentially labeled chromosome-specific painting probes (24xCyte kit MetaSystems, Altlussheim, Germany) was used according to the protocol recommended by Human Multicolor FISH kit (MetaSystems, Altlussheim, Germany). Briefly, the slides were incubated at 70°C in saline solution (2xSSC), denatured in NaOH, dehydrated in ethanol series, air-dried, covered with 10 &L of probe cocktail (denatured), and hybridized for 2 days at 37°C. Slides were then washed with post-hybridization buffers, dehydrated in ethanol series, and counterstained with 10 &L of DAPI/antifade. Signal detection and subsequent metaphase analysis were done using the Metafer system and Metasytems' ISIS software (software for spectral karyotypes) (Carl Zeiss, Metasystems, GmbH, Germany) ([@bib82],[@bib83]).

Immunohistochemistry (IHC)
--------------------------

Immunohistochemistry for ER and PR was carried out on MCF7, T47D, BT474, and SKBR3 cells at baseline and treated with E~2~ (10^&8 ^mol L^&1^) and TAM (10^&6 ^mol L^&1^) for 24, 48, and 96 h. At each time point, cells were harvested, formalin-fixed, and paraffin-embedded according to standard procedures. Sections of the representative cell block were cut at 3 &m and mounted on electrostatically charged slides. Immunohistochemistry was performed using an automated immunostainer (Ventana BenchMark XT AutoStainer; Ventana Medical Systems, Tucson, AZ, USA) with antibodies against ER (Clone SP1, prediluted, Ventana) and PR (Clone 1A6, 1:50 diluted; Leica Biosystems). Positive and negative controls were included for each immunohistochemical run. IHC slides were scanned by using the Aperio system (ScanScope CS System, Vista, CA, USA) for automated counting. To ensure the reliability of the automatic assessment, stainings were reviewed by two pathologists (A S and C M).

Data analysis
-------------

The profile of numeric and structural chromosomal changes observed after treatments was determined in comparison with the control. Student's *t*-test was performed to compare cell proliferation of treated cell lines with untreated cell lines. Fisher's exact test was applied to compare conventional and molecular cytogenetic results from treated cell lines with the results from control cell lines (differences in single chromosomal alterations between control and treated cells). In addition, Pearson's *&*^2^ test was used to investigate a possible association between occurrence of specific chromosomal aberrations at each time point and effect on proliferation. The coefficient of variation, CV (=100 × standard deviation/mean), was used to calculate the variability in the frequency of new chromosomal alterations, observed after E~2~ and TAM treatments (24, 48, and 96 h). *P* values \<0.05 were considered as statistically significant. All statistical analyses were performed using the SPSS v.20 program.

Results
=======

General effects on chromosomes induced by low doses of E~2~ and TAM
-------------------------------------------------------------------

Control cells harbored the same alterations previously reported ([@bib82],[@bib83]). Both E~2~ and TAM treatments rapidly induced *de novo* chromosomal alterations.

The frequency of new chromosomal alterations changed along E~2~ and TAM treatments for all cell lines, and while the frequency of some chromosomal abnormalities remained constant along treatments, other increased or decreased (CV range: 3--96%) ([Fig. 1](#fig1){ref-type="fig"} and [Supplementary Table 1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1), see section on supplementary data given at the end of this article). This variability is not surprising, considering that genetic diversification, clonal expansion, and clonal selection are events widely reported in cancer and also associated with therapeutic interventions ([@bib33]).Figure 1Frequency of chromosomal alterations observed *de novo* after E~2~ and TAM treatments. The frequency of each chromosomal alteration is indicated along the treatments (24, 48, and 96 h) using a color code for each category. (A) MCF7 cells. (B) T47D cells. (C) BT474 cells. (D) SKBR3 cells. A full colour version of this figure is available at <http://dx.doi.org/10.1530/ERC-16-0078>.

More in detail, compared with control cells (T24 h and T96 h without treatment), low doses of E~2~ increased the chromosome ploidy in all cell lines ([Table 1A](#tbl1){ref-type="table"}), whereas TAM was effective on ploidy only in HER2+ cell lines ([Table 1B](#tbl1){ref-type="table"}). Some of the alterations were observed in more than one cell line and were induced by both E~2~ and TAM ([Fig. 2](#fig2){ref-type="fig"} and [Supplementary Table 2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). In [Fig. 3](#fig3){ref-type="fig"}, the chromosomal aberrations induced or increased after E~2~ or TAM treatments as compared with control cells are represented. Low doses of E~2~ produced numerical alterations represented mainly by gain of whole chromosomes in all cell lines. Low doses of both E~2~ and TAM induced *de novo* structural aberrations such as isochromosomes (i) in BT474 and SKBR3 cells and dicentric (dic) chromosomes in T47D and BT474 cells. Both treatments increased derivative (der) chromosomes in HER2+ cells only, whereas additional material of unknown origin (add) was a *de novo* observation only in T47D after E~2~ treatment.Figure 2Clonal chromosomal abnormalities induced by E~2~ and TAM in four breast cancer cell lines at each treatment time point. The presence of a given chromosomal alteration after E~2~ and/or TAM treatment in one or more cell lines is color coded according to the legend at the bottom. A full colour version of this figure is available at <http://dx.doi.org/10.1530/ERC-16-0078>. Figure 3Total number of chromosomal aberrations induced after E~2~ (A) and TAM (B) treatment at 24, 48, and 96 h in MCF7, T47D, BT474, and SKBR3 cell lines. Numerical chromosomal alterations: gains and losses. Structural chromosomal alterations: add, additional material of unknown origin; del, deletion; der, derivative chromosome; dic, dicentric chromosome;  i, isochromosome. A full colour version of this figure is available at <http://dx.doi.org/10.1530/ERC-16-0078>. Table 1Percentage of cells with polyploidy in MCF7, T47D, BT474, and SKBR3 cell lines. (A) Control and E~2~ treated. (B) Control and TAM treated. A hundred metaphases were analyzed for both control and for each of the treatments with E~2~ and TAM.**TreatmentsMCF7T47DBT474SKBR3**4n\>4n3n\>3n4n\>4n4n\>4nA Control98296410008119 E2. 24 h8515871388126337 E2. 48 h8020782277235248 E2. 96 h6139673370305050B Control98296410008119 TAM. 24 h97385159462476 TAM. 48 h9919829822476 TAM. 96 h991100084163070

Many of the altered chromosomal regions in the cell lines analyzed contain important genes involved in breast cancerogenesis including *BCAR3* (1p22), *CENPF* (1q41), *ENAH* (1q42), and *AKT3* (1q44) associated with aneuploidy, chromosomal instability, and anti-estrogen resistance ([@bib68], [@bib23], [@bib70]); *FHIT*, *FOXP1*, and *LRIG1* on 3p14 correlated with chromosomal instability and anti-estrogen resistance ([@bib11], [@bib5], [@bib63]); *AKAP9*(7q21), *[DMTF1]{.ul}*(7q21), and *HIPK2* (7q32) involved in the assembly of protein kinases to the centrosome and in growth arrest ([@bib30], Sreeramaneni *[et al]{.ul}*. 2005, Pierantoni *[et al]{.ul}*. 2007); *E2F1* (20q11.22) and *MAPRE1* (20q11.1-11.23) involved in the regulation of the mitotic cell division process, regulation of microtubule dynamic instability, and in cell cycle control ([@bib95]), among others ([Table 2](#tbl2){ref-type="table"}). Table 2Selected breast cancer oncogenes and tumor suppressor genes present in the chromosomal regions affected by chromosomal abnormalities in MCF7, T47D, BT474, and SKBR3 cell lines following treatment with E~2~ and TAM for 24, 48, and 96 h.Chromosomal regionCell lineGenesMCF7T47DBT474SKBR3FunctionReferences1p13.3*CSF1*XCell proliferation[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)1p22*BCL10*XXOncogene, apoptosis[@bib60]1p22*BCAR3*XXCell proliferation, resistance in breast cancer cell lines[@bib68], [@bib23], [@bib70]1p32p31*JUN*XOncogen[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)1p36.21*PRDM2*XTumor suppressor gene, binds to ER. Transcriptional regulation,  E~2~ effector action[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)1q11*MUC1*XCell physiology and pathology, up-regulated in breast cancer[@bib104]1q21.1*CA14*XBasic cellular metabolism; breast cancer[@bib71], [@bib8], [@bib10]1q21.3*PIP5K1A*XCell proliferation, breast cancer[@bib71], [@bib8], [@bib10]1q25.2-q25.3*COX2*XInflammation and mitogenesis[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)1q32*KISS*XCell motility, oncogene[@bib71], [@bib10], [@bib8]1q31*PTGS2*XInflammation, tumorigenesis[@bib24]1q41*CENPF*XKinetochore assembly[@bib68], [@bib23], [@bib70]1q42.12*ENAH*XCell shape and movement[@bib68], [@bib23], [@bib70]1q44*AKT3*XProliferation, cell survival, and tumorigenesis[@bib68], [@bib23], [@bib70]3p14*FHIT*XTumor suppressor gene; resistance to tamoxifen in MCF7 cells[@bib11]3p14*FOXP1*XTumor suppressor gene, multiple types of cancers[@bib5]3p14*LRIG1*XSuppressor of receptor tyrosine kinases, breast cancer[@bib63]6p25*TFAP2A*XTumor supressor gene, breast cancer[@bib89]6p25*DUSP22*XSignaling pathway, breast cancer[@bib21]7p22*GPR30*XG protein-coupled receptor 30, drug resistance[@bib99]7p22*SDK1*XCell adhesion protein, breast cancer[@bib21]7q11.2*LIMK1*XOrganization of actin cytoskeleton[@bib54]7q11.2*HSPB1*XOncogenesis and resistance to various anti-cancer therapies[@bib54]7q11.2*AUTS2*XBreast cancer[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)7q21*AKAP9*XProtein that assembles protein kinases on the centrosome[@bib30]7q21*DMTF1*XTranscriptional activator promoting p53/TP53-dependent growth arrest.[@bib94]7q32*HIPK2*XTumor supressor gene, breast cancer[@bib73]7q36*MNX1*XTranscription factor, breast cancer[@bib69]7q36*MLL3*XTranscriptional coactivation, breast cancer[@bib69]8p22*MTUS1*XXTumor suppressor gene, breast cancer[@bib81]8p23*CTSB*XXMetabolism, angiogenesis, invasion, and metastasis in breast cancer[@bib79]8p23*CSMD1*XXTumor supressor gene, poor survival in breast cancer[@bib46],  [@bib21]8p23*DLC1*XXTumor suppressor gene, breast cancer[@bib75]9p24*JAK2*XXProtein tyrosine kinase of the non-receptor type, breast cancer[@bib21]9p24*RLN2*XXDevelopment of mammary gland. Invasion in breast cancer[@bib78]9p24*KANK1*XXTumor supressor gene, breast cancer[@bib21]9p24*JMJD2C*XXDemethylase, breast cancer[@bib21]10p11.2*ABI1*XCell growth inhibitor, cancer progression, and prognosis[@bib20]11p15*HRAS*XXSignal transduction, tumor aggressiveness in breast cancerHae-Young [@bib103]11p15*CTSD*XXInvasion and metastasis[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)11p15*CD151*XXSignal transduction, breast cancer[@bib42]11p15*RRM1*XXTumor supressor gene, DNA repair[@bib49]11p15*MMP26*XXMigration and angiogenesis, breast cancer[@bib21]11p15*CDKN1C*XXNegative regulator of cell cycle[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)11q23*ATM*XTumor supressor gene, DNA repair[@bib84]11q23*CRYAB*XMolecular chaperone function, metastasis in breast cancer[@bib14]11q23*ETS1*XTranscripction factor, breast cancerLincoln & Bove (2005)11q23*CCND1*XCell cycle G1/S transition, tumorigenesis in various carcinomas[@bib64]11q23*PGR*XSignal transduction, breast cancer[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)15q10*BUB1B*XMitotic spindle checkpoint, chromosomal instability in breast cancer[@bib90]15q15*THBS1*XInvasion, metastasis, angiogenesis[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)15q26.3*IGF1R*XCell growth and survival control, breast cancer[@bib47]17q24*BIRC5*XApoptosis inhibition[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)18q21.1*SMAD4*XTranscription factor, breast cancer[@bib21], [@bib69]18q21.1*BCL2*XCell death, breast cancer[@bib21]18q21.2*DCC*XApoptosis, breast cancer[@bib50]19q13*ATF5*XCell cycle progression, breast cancer[@bib3], [@bib100]19q13*LILRA6*XReceptor for class I MHC antigens, breast cancer[@bib21]19q13*CYP2A6*XMetabolism of pharmaceutical drugs, directly induced by estradiol[@bib36]19q13*TGFB1*XCell division and death, imply in tamoxifen resistance in breast cancer[@bib1], [@bib75], [@bib43], [@bib41]19q13*CEACAM1*XCell survival, differentiation, and growth, breast cancer[@bib65], [@bib80]20q11.22*E2F1*XTumor suppressor gene[@bib95]20q13.1*CDH4*XCell adhesion proteins, breast cancer[@bib21]20q13.1*MMP9*XMetastasis and cancer cell invasion, breast cancer[@bib51]20q13.31*AURKA*XCell proliferation, breast cancer[@bib18]22q13*ATF4*XAdaptation of cells to stress factors, multidrug resistant gene[@bib39]22q13*SERHL2*XBreast cancer[@bib21]22q13*LARGE*XBreast cancer[@bib21]22q13*XRCC6*XApoptosis induction, breast cancer[@bib69]

Combined effects on cell proliferation and  chromosomal alterations
-------------------------------------------------------------------

We then more specifically analyzed the chromosomal alterations in comparison with the effects on proliferation induced by E~2~ and TAM in each cell line. Although we did not observe a specific pattern of chromosomal aberrations that significantly correlated with either increased or decreased proliferation rates across cell lines, single aberrations significantly correlated with increase  or decrease of proliferation within each cell line, as detailed below.

In MCF7 cell line, as expected, E~2~ treatment significantly stimulated cell proliferation (*P* \< 0.0001, Student's *t*-test; [Fig. 4A](#fig4){ref-type="fig"}) and induced more structural than numerical chromosomal alterations (*P *≤ 0.05, Fisher's exact test; [Fig. 2](#fig2){ref-type="fig"}, [Supplementary Tables 2, 3 and 4](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). However, only a statistically significant increase in nullisomy of chromosome 18 and 20 (*P *\< 0.01) together with del(7)(q21) and del(7)(q32) was constantly observed at all treatment time points ([Figs 2](#fig3){ref-type="fig"} and [4A](#fig4){ref-type="fig"}, [Supplementary Tables 3 and 4](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). Figure 4Effects of E~2~ (A) and TAM (B) treatment for 24, 48, and 96 h on proliferation and corresponding chromosomal alterations in MCF7 cells. Error bars represent mean standard deviation of 24 separate experiments. Chromosomal abnormalities induced at each treatment time point are indicated. A full colour version of this figure is available at <http://dx.doi.org/10.1530/ERC-16-0078>.

TAM treatment inhibited significantly MCF7 cell proliferation (*P* \< 0.01) ([Fig. 4B](#fig4){ref-type="fig"}). Eleven chromosomes  (1, 2, 6, 7, 8, 10, 11, 17, 15, 19, and 20) varied in their copy number, but most of these alterations, except for +1 and &6, were observed only in one of the treatment time points and were considered as sporadic ([Supplementary Table 3](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). As compared with control cells, six additional complex chromosomal aberrations, del(1)(p22), del(3)(p13), der(7)t(7;20)(p22;?)t(7;20)(?;?), add(8)(p23), der(9)t(9;21)(p24;?)t(8;21)(?;?), and der(11)t(4;11)(?;p15) ([Figs 2](#fig2){ref-type="fig"}, [4B](#fig4){ref-type="fig"}, [5A](#fig5){ref-type="fig"} and [Supplementary Table 2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)), were identified and constantly present at each time point. In addition, der(11)t(4;11)(?;p15) was observed in both E~2~- and TAM-treated cells. An increase in the frequency of two pre-existing alterations del(7)(q11.2) and del(12)(p11.2) was also observed after both E~2~ and TAM treatment ([Supplementary Table 4](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)).Figure 5Representative images of chromosomal abnormalities observed throughout the treatment duration with either E~2~ or TAM. (A) MCF7 cells, (B) T47D cells, (C) BT474 cells, and (D) SKBR3 cells. Rearranged chromosomes are visualized by G-banding technique on the left and by M-FISH on the right. The chromosomes involved in the rearrangement are numbered on the right hand side of the chromosomes. A full colour version of this figure is available at [http://dx.doi.org/10.1530/ERC-16-0078](http://http://dx.doi.org/10.1530/ERC-16-0078).

T47D cells responded to E~2~ treatment with the highest growth advantage at 96 h ([Fig. 6A](#fig6){ref-type="fig"}). This effect corresponded to a more complex karyotype of E~2~-stimulated cells than control cells with the following additional alterations, +3, &7, &8, der(11)t(4;11)(?;p15), &14, +16, and der(17)t(17;21)(q24;?) (*P* \< 0.01), observed at least at two time points ([Figs 2](#fig2){ref-type="fig"}, [5B](#fig5){ref-type="fig"}, [6A](#fig6){ref-type="fig"} and [Supplementary Table 2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). In analogy to MCF7 cells, an increase in the frequency of some pre-existing numerical alterations was observed after both treatments in T47D cells ([Supplementary Table 5](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)).Figure 6Effects of E~2~ (A) and TAM (B) treatment for 24, 48, and 96 h on proliferation and corresponding chromosomal alterations in T47D cells. Error bars represent mean standard deviation of 24 separate experiments. Chromosomal abnormalities induced at each treatment time point are indicated. A full colour version of this figure is available at <http://dx.doi.org/10.1530/ERC-16-0078>.

The effect of TAM on cell growth inhibition was much lower than that observed in MCF7 cells and disappeared at 96 h ([Fig. 6B](#fig6){ref-type="fig"}). As compared with untreated controls, only three additional numerical alterations were constantly present (+6, &14, and &17) (*P* \< 0.01, Fisher's exact test) after TAM ([Fig. 6B](#fig6){ref-type="fig"}, [Supplementary Tables 5 and 6](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). On the contrary, some chromosomal rearrangements present in the control cells could not be observed after E~2~ and TAM treatment ([Supplementary Table 6](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). In T47D, both E~2~ and TAM induced loss of chromosomes 7, 8, and 14, whereas an additional chromosome 19 was induced by both treatments in T47D and SKBR3 cells.

In BT474 cells, both E~2~ and TAM treatments induced two peaks of proliferation at 24 and 96 h. G-banding and M-FISH analyses of both E~2~- and TAM-treated BT474 cells identified the same new chromosomal complex rearrangements der(3)t(3;8)(p14;?), der(8)t(8;17)(p23;?)t(6;17)(?;?), and der(15;15)(q10;q10) at each time point ([Figs 2](#fig2){ref-type="fig"}, [5C](#fig5){ref-type="fig"}, [7](#fig7){ref-type="fig"} and [Supplementary Table 2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). Additional new rearrangements were observed after E~2~ ([Fig. 7A](#fig7){ref-type="fig"}, [Supplementary Tables 7 and 8](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)) or after TAM treatment ([Fig. 7B](#fig7){ref-type="fig"}) at least at two time points. An increase in the frequency of some preexisting chromosomal alterations (*P* ≤ 0.01) was also observed ([Supplementary Tables 7 and 8](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)).Figure 7Effects of E~2~ (A) and TAM (B) treatment for 24, 48, and 96 h on proliferation and corresponding chromosomal alterations in BT474 cells. Error bars represent mean standard deviation of 24 separate experiments. Chromosomal abnormalities induced at each treatment time point are indicated. A full colour version of this figure is available at <http://dx.doi.org/10.1530/ERC-16-0078>.

Finally, in SKBR3 (ER&/HER2+), only 96 h of E~2~ and TAM treatment significantly increased cell proliferation (*P* \< 0.006 and *P* \< 0.024) ([Fig. 8](#fig8){ref-type="fig"}), as compared with controls. However, *de novo* chromosomal alterations were already observed after 24 h of treatment. SKBR3 control cells displayed a complex karyotype with a particularly high frequency of chromosome 1 aberrations. After 24 h of E~2~ and TAM treatment, the karyotype became even more complex with the appearance of new chromosome 1 abnormalities, such as for instance dic(1;19)(p11;q13) and i(1)(q10) (*P* \< 0.05) ([Figs 2](#fig2){ref-type="fig"}, [5D](#fig5){ref-type="fig"}, [8A, B](#fig8){ref-type="fig"} and [Supplementary Table 2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)). A statistically significant increase in the frequency of some pre-existing chromosomal abnormalities was observed in SKBR3 as well ([Supplementary Tables 9 and 10](http://erc.endocrinology-journals.org/cgi/content/full/ERC-16-0078/DC1)).Figure 8Effects of E~2~ (A) and TAM (B) treatment for 24, 48, and 96 h on proliferation and corresponding chromosomal alterations in SKBR3 cells. Error bars represent mean standard deviation of 24 separate experiments. Chromosomal abnormalities induced at each treatment time point are indicated. A full colour version of this figure is available at <http://dx.doi.org/10.1530/ERC-16-0078>.

Expression of hormone receptors following treatment
---------------------------------------------------

IHC analysis showed that ER levels remained unchanged after E~2~ and TAM addition in MCF7, T47D, and SKBR3 cells, whereas in BT474 cells we observed an increase in both ER and PR expression after TAM treatment in parallel with an increase in proliferation (all time points; data not shown). These results support the hypothesis that TAM could play an estrogen agonist role in ER+/HER2+ cells (BT474), as it has been previously suggested ([@bib74], [@bib13], [@bib52]) and shown in other cell line models ([@bib93]). In addition, increased PR expression in human breast cancers has been associated with TAM resistance ([@bib19]).

E~2~ addition increased PR expression also in the other ER+ cell lines (MCF7 and T47D). In contrast, after TAM treatment, a reduced PR expression was observed in MCF7 and T47D cells (data not shown). This is in line with previous observations showing that when estradiol is acting, TAM is not able to increase the level of occupied estrogen receptors and it acts as an anti-estrogen by decreasing the high level of progesterone receptors previously induced by estradiol ([@bib12]).

Discussion
==========

Short-term endocrine treatment has been proposed as an alternative to long-term neoadjuvant therapy to assess tumor response ([@bib26]). In addition, low doses of TAM have been proposed for chemoprevention in women at high risk of developing breast cancer ([@bib55]). Hypersensitivity to low levels of estrogen has been suggested as a potential mechanism of endocrine therapy resistance ([@bib45]). In addition, residual amounts of estrogen may still be present after treatment with aromatase inhibitors, which function by reducing estrogen biosynthesis ([@bib25]). E~2~ binding to tubulin may induce a cell cycle arrest in G2/M and generate chromosomal instability ([@bib87], [@bib88], [@bib4], [@bib56]).

In this study, we observed that low doses of both E~2~ and TAM were able to induce structural chromosomal aberrations (deletions, isochromosomes, translocations, and dicentric chromosomes) in both ER+ and ER& breast cancer cells.

Dicentric chromosomes, which contain two functional centromeres, can lead to extensive chromosomal rearrangements, including translocations with other chromosomes ([@bib32]). Chromosomal translocations, a frequent event observed after E~2~ and TAM treatment, may lead to the production of tumor-specific fusion proteins, which are often transcription factors ([@bib77]). For example, der(11)t(4;11)(?;p15) was observed in both E~2~- and TAM-treated MCF7 cells and in E~2~-treated T47D. Several genes are located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region ([@bib37]).

While some complex chromosomal alterations were consistent throughout the treatments, other disappeared. The above could be related with the instability of such alterations. After treatment, unstable chromosomal alterations could be randomly fused to form more complex chromosomal rearrangements including translocations, dicentric chromosomes, and duplications ([@bib92], [@bib105]). Another possible explanation, which can be strictly connected to the previous, is the possibility of clonal selection of the fittest clone ([@bib35], [@bib62], [@bib22]).

When chromosomal alterations were analyzed with respect to proliferation, some specific patterns within each cell line were observed. For instance, T47D cells showed a poorer response to TAM compared with MCF7 cells and mainly displayed numerical chromosomal alterations following treatment. The ER+/HER2+ BT474 cells showed the highest increase in cell proliferation after 24 h of treatment with both E~2~ and TAM compared with control cells. Cell growth increase after TAM treatment may indicate an estrogen agonist activity, possibly enhanced by the co-expression of ER and HER2 ([@bib74], [@bib13], [@bib52]). Indeed, the cross talk between ER pathways and growth factor receptor pathways (EGFR, IGF-1, and HER2) has been involved in cell proliferation, survival, and resistance to endocrine therapy (TAM) in breast cancer ([@bib102], [@bib74], [@bib13]). However, in our study, after 48 h of TAM treatment cell proliferation decreased and increased again at 96 h. This decrease/increase may be explained through a clonal selection, with survival of those cells that acquired chromosomal abnormalities fostering proliferative and survival advantages.

As expected, our results confirm that the induction and inhibition of cell proliferation by E~2~ and TAM, respectively, is dependent on the presence of ER. However, in the  ER&/HER2+ SKBR3 cells, these agents induced a high frequency of chromosomal abnormalities and a small increase in proliferative activity at 96 h of treatment. Both effects may be due to the presence of the G protein-coupled receptor 30 (GPCR30), an estrogen transmembrane receptor, which modulates both rapid non-genomic and genomic transcriptional events of estrogen ([@bib97],  [@bib15], [@bib58], [@bib16]). On the other hand, E~2~ may induce chromatin structural changes in both ER+ and ER& breast cancer cells through ERR ([@bib38]). The ability of estrogens and its metabolites (catechol estrogens) to induce mutations in cancer cells has been demonstrated both *in vivo* and *in vitro* ([@bib59], [@bib101]), being observed that estrogens induce overexpression of the *Aurora A* and *B* genes ([@bib57]), cause genomic instability ([@bib6], [@bib98], [@bib2], [@bib44], [@bib53], [@bib101]), and induce chromosomal aberrations, thus confirming its properties as mutagenic and carcinogenic factor. Along the same lines, in luminal breast tumors, up-regulation of ER signal pathway has been associated with cell proliferation, cell survival, and therapy resistance ([@bib102], [@bib74], [@bib13]). Although factors such as local synthesis of estrogen ([@bib31]), autocrine regulation of cell proliferation ([@bib31], [@bib96]), and cross talk with signaling from other growth factors have been associated with this up-regulation, the mechanisms underlying the action of ER are still not fully understood.

In summary, our results demonstrate that low doses of E~2~ and TAM may favor the production of specific chromosomal abnormalities in both ER+ and ER- breast cancer cells. This genotoxic effect is higher in those cell lines with *HER2* gene amplification. The induction of chromosomal alterations by E~2~ and TAM observed *in vitro* may support the contention that a careful assessment of the risk and the benefit of E~2~ and TAM administration should be considered. Indeed, the novel chromosomal rearrangements originated following E~2~ and TAM exposure may contribute to stimulate cell proliferation leading to survival advantages and allowing for selection of clones with new chromosomal abnormalities. *In vivo* studies that may help address the biological effect of such alterations and ascertain whether or not these may be responsible for treatment resistance are warranted.

Supplementary data
==================

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/ERC-16-0078>.

Declaration of interest
=======================

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
=======

This work was funded by the Italian Association of Cancer Research, AIRC (MFAG13310 to C M), by the Ministry of University (Ex 60% 2014 and 2015 to C M) and by Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute 2013 (to A S).

Authors' contribution statement
===============================

M R L performed the experiments and analyzed and interpreted the data. L V d C acquired and analyzed G-banding and M-FISH karyotypes. R R and L A participated in cell culture experiments. T M performed IHC. N R performed statistical analyses and participated in data analysis. I C participated in data analysis. C M and A S conceived and supervised the study and analyzed and interpreted the data. M R L, C M, and A S wrote the manuscript.

The authors would like to acknowledge technical support in immunohistochemical and M-FISH analysis by Mrs Maria Stella Scalzo, Mrs Stefania Bolla, and Mr Marco Cupo as well as assistance in manuscript preparation by Mrs. Paola Critelli, Mr Jacopo De Gregori, and Mr Lorenzo Di Filippo (Liceo Scientifico Scienze Applicate, Asti).

[^1]: (C Marchiò and A Sapino contributed equally to this work)
